drugset
drugset / Trial / NCT02996487

Screening to Prophylax Against Clostridium Difficile Infection -

NCT02996487 ↗

Phase 4 Completed 1294 enrolled Corewell Health East
RandomizedParallel-groupTriple-blindPrevention

Summary

The goal of this study is to evaluate whether using vancomycin orally can prevent CDI in patients who are colonized with C. difficile who are admitted to the hospital and need antibiotics for another infection.

Timeline

Start
2016-12-19
Primary completion
2023-06-28
Completion
2023-06-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Vancomycin Other / unclassified 125 mg Oral

Indications

Clostridium difficile colitis